Coherus loses commercial chief amid exit from biosimilar space
23rd April 2025 Uncategorised 0Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. As the biotech completes its pivot from biosimilars to novel immuno-oncology programs, Reider has resigned as chief commercial officer to pursue other opportunities.
More: Coherus loses commercial chief amid exit from biosimilar space
Source: fierce